MULTIPLE ELECTROLYTE ADDITIVE INJ 29.8 MG — DIN 00421952
POTASSIUM CHLORIDE : 29.8 MG MAGNESIUM SULFATE : 19.8 MG SODIUM CHLORIDE : 46.6 MG CALCIUM GLUCONATE : 20.6 MG · INTERNATIONAL MEDICATION SYSTEMS LTD. · LIQUID · wholesale supply in Canada
Health Canada status: CANCELLED POST MARKET
What is MULTIPLE ELECTROLYTE ADDITIVE INJ?
MULTIPLE ELECTROLYTE ADDITIVE INJ 29.8 MG contains POTASSIUM CHLORIDE : 29.8 MG MAGNESIUM SULFATE : 19.8 MG SODIUM CHLORIDE : 46.6 MG CALCIUM GLUCONATE : 20.6 MG. It is listed in the Health Canada Drug Product Database under DIN 00421952, held by INTERNATIONAL MEDICATION SYSTEMS LTD., supplied as LIQUID for INTRAVENOUS administration. Health Canada currently lists it as cancelled post market, status dated 15-Aug-1997. This Drug Identification Number is no longer authorized for sale in Canada, so Nexara does not supply it. The record is kept here because buyers still meet the number on old formularies, purchase orders and tender documents; Nexara can help identify an authorized alternative.
How much does Combinations Of Electrolytes cost around the world?
Combinations Of Electrolytes is listed on 4 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Czechia publishes a max producer price (ex-factory); Hungary publishes a producer price (ex-factory); Iceland publishes a max wholesale. Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Hungary | producer price (ex-factory) | 5 | 5 | HUF███.██ |
| Czechia | max producer price (ex-factory) | 1 | 1 | CZK███.██ |
| Iceland | max wholesale | 1 | 1 | ISK███.██ |
| Luxembourg | reimbursement | 1 | 1 | EUR███.██ |
8 pack listings across 8 brand entries and 4 price bases, refreshed 05 Sep 2026. Ranges span every Combinations Of Electrolytes pack in that market, so a high figure is usually a larger pack rather than the same product.
This table is a regulatory record of where the molecule is listed. The DIN on this page is no longer authorized for sale in Canada, so Nexara does not quote it — see the alternatives above.
Is there a generic Combinations Of Electrolytes in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
5 holders have a Canadian DIN containing Combinations Of Electrolytes, across 10 DINs, of which 1 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| PFIZER CANADA ULC | 1 | 1 | TPN ELECTROLYTES | Sourceable in Canada |
| PHARMACEUTICAL PARTNERS OF CANADA INC | 4 | 0 | LYPHOLYTE, M.T.E.-4, M.T.E.-4 CONCENTRATED, M.T.E.-6 CONCENTRATED | No marketed DIN |
| INTERNATIONAL MEDICATION SYSTEMS LTD. | 2 | 0 | CARBICARB INJECTION, MULTIPLE ELECTROLYTE ADDITIVE INJ | No marketed DIN |
| LYPHOMED, DIVISION OF FUJISAWA CANADA INC. | 2 | 0 | LYPHOLYTE MULTI-ELECTROLYTE CONC INJ, MTE 4 INJ | No marketed DIN |
| B. BRAUN MEDICAL INC | 1 | 0 | HYPERLYTE (MULTI-ELECTROLYTE CONCENTRATE) | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 29.8 MG |
|---|---|
| Dosage form | LIQUID |
| Route | INTRAVENOUS |
Pack detail is kept as a regulatory record. This DIN is no longer authorized for sale in Canada, so Nexara does not quote this pack.
Substance and classification
| Active substance | Combinations Of Electrolytes |
|---|---|
| ATC code | B05XA30 |
| AHFS class | 72:00.00 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 00421952 |
|---|---|
| DIN (unpadded, as printed on some documents) | 421952 |
| Brand name | MULTIPLE ELECTROLYTE ADDITIVE INJ |
| Generic / active ingredient | POTASSIUM CHLORIDE : 29.8 MG MAGNESIUM SULFATE : 19.8 MG SODIUM CHLORIDE : 46.6 MG CALCIUM GLUCONATE : 20.6 MG |
| Market authorization holder | INTERNATIONAL MEDICATION SYSTEMS LTD. |
| Health Canada schedule | Ethical |
| ATC code | B05XA30 |
| ATC anatomical main group | B — Blood and blood-forming organs |
| ATC therapeutic subgroup | B05XA |
| Current status | CANCELLED POST MARKET |
| Status date | 15-Aug-1997 |
| Original market date | 1978-12-31 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
1 of 10 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| TPN ELECTROLYTES | 16.55 MG | SOLUTION | PFIZER CANADA ULC | MARKETED | 00590215 |
| CARBICARB INJECTION | 35 MG | LIQUID | INTERNATIONAL MEDICATION SYSTEMS LTD. | CANCELLED POST MARKET | 00757004 |
| HYPERLYTE (MULTI-ELECTROLYTE CONCENTRATE) | 690 MG / 25 ML | LIQUID | B. BRAUN MEDICAL INC | CANCELLED POST MARKET | 01963910 |
| LYPHOLYTE | 2.5 G / 20 ML | SOLUTION | PHARMACEUTICAL PARTNERS OF CANADA INC | CANCELLED POST MARKET | 02139618 |
| LYPHOLYTE MULTI-ELECTROLYTE CONC INJ | 43 MG | LIQUID | LYPHOMED, DIVISION OF FUJISAWA CANADA INC. | CANCELLED POST MARKET | 01944940 |
| M.T.E.-4 | 1 MG | SOLUTION | PHARMACEUTICAL PARTNERS OF CANADA INC | CANCELLED POST MARKET | 02139278 |
| M.T.E.-4 CONCENTRATED | 10 MCG | SOLUTION | PHARMACEUTICAL PARTNERS OF CANADA INC | CANCELLED POST MARKET | 02139251 |
| M.T.E.-6 CONCENTRATED | 5 MG | SOLUTION | PHARMACEUTICAL PARTNERS OF CANADA INC | CANCELLED POST MARKET | 02139235 |
| MTE 4 INJ | 1 MG | LIQUID | LYPHOMED, DIVISION OF FUJISAWA CANADA INC. | CANCELLED POST MARKET | 01945319 |
2 · Same class — other molecules in ATC B05XA
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Sodium Chloride | 0.45% SODIUM CHLORIDE INJECTION USP · 0.9% SODIUM CHLORIDE INJECTION · 0.9% SODIUM CHLORIDE INJECTION USP · 0.9% SODIUM CHLORIDE INJECTION, USP · +23 more | 37 | 11 | Yes |
| Potassium Chloride | POTASSIUM CHLORIDE FOR INJECTION CONCENTRATE · POTASSIUM CHLORIDE FOR INJECTION CONCENTRATE USP · POTASSIUM CHLORIDE FOR INJECTION CONCENTRATE, USP (2 MEQ/ML) · POTASSIUM CHLORIDE INJ 149MG/ML USP · +7 more | 17 | 7 | Yes |
| Sodium Bicarbonate | SODIUM BICARBONATE 5% INJ 50MG/ML USP · SODIUM BICARBONATE 5% INJ 5GM/100ML USP · SODIUM BICARBONATE INJ 4.2% · SODIUM BICARBONATE INJ 7.5% · +6 more | 18 | 5 | Yes |
| Electrolytes In Comb With Other Drugs | ADDNUTRIV · MICRO +4 REGULAR STRENGTH · MICRO PLUS 4 CONCENTRATE · MICRO PLUS 5 CONCENTRATE · +10 more | 14 | 5 | Yes |
| Calcium Gluconate | 2% CALCIUM GLUCONATE IN SODIUM CHLORIDE INJECTION · CALCIUM GLUCONATE IN SODIUM CHLORIDE INJECTION · CALCIUM GLUCONATE INJECTION USP 10% · CALCIUM GLUCONATE INJECTION, USP 10% | 5 | 5 | Yes |
| Magnesium Sulphate | MAGNESIUM SULFATE IN WATER FOR INJECTION · MAGNESIUM SULFATE INJ 50% · MAGNESIUM SULFATE INJECTION 50% USP · MAGNESIUM SULFATE INJECTION BP · +3 more | 9 | 4 | Yes |
| Zinc Sulfate | MICRO ZN · ZINC SULFATE INJECTION, USP | 4 | 4 | Yes |
| Potassium Phos Incl Comb W/0th Pot. Salts | POTASSIUM PHOSPHATE INJ 3MMP/ML · POTASSIUM PHOSPHATE MONOBASIC INJECTION · POTASSIUM PHOSPHATES · POTASSIUM PHOSPHATES INJ · +1 more | 5 | 3 | Yes |
| Calcium Chloride | CALCIJECT INJ 100MG/ML · CALCIUM CHLORIDE INJECTION BP · CALCIUM CHLORIDE INJECTION USP · CALCIUM-35 0.25 - 10 · +1 more | 5 | 2 | Yes |
| Sodium Acetate | 16.4% SODIUM ACETATE INJECTION, USP · SODIUM ACETATE INJ 328MG/ML USP · SODIUM ACETATE INJECTION USP · SODIUM ACETATE INJECTION, USP | 5 | 2 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC B05X
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| B05XC | Vitamins | 9 | 2 |
| B05XX | Trometamol | 1 | 0 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is MULTIPLE ELECTROLYTE ADDITIVE INJ called?
The same molecule, Combinations Of Electrolytes, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Ekyflogyl | Latin | Iceland |
| OTIPAX | Latin | Czechia |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.